{
    "clinical_study": {
        "@rank": "46754", 
        "arm_group": {
            "arm_group_label": "Radiotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the incidence of urinary and rectal acute side\n      effects of a pelvic and prostatic intensity-modulated arctherapy with simultaneous\n      integrated boost (SIB-IMRT)combined with long-term androgen deprivation for patients with\n      high risk localized prostate cancer"
        }, 
        "brief_title": "Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer", 
        "completion_date": {
            "#text": "October 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed adenocarcinoma of the prostate\n\n          2. High risk localized adenocarcinoma defined by at least one of the following criteria:\n\n               -  Clinical stage T2c, T3 or T4\n\n               -  Gleason score \u2265 8\n\n               -  Prostate-specific antigen (PSA)\u2265 20 ng/ml and \u2264 100 ng/ml\n\n          3. Patient cN0, pN0 or Nx (negative lymphadenectomy or no lymphadenectomy)\n\n          4. No pelvic adenopathy \u2265 15 mm on CT or MRI,\n\n          5. Absence of bone and/or visceral metastasis\n\n          6. Androgen deprivation beginning no later than the day of radiotherapy and up to six\n             months before irradiation\n\n          7. Absence of prior pelvic radiotherapy,\n\n          8. Absence of surgical treatment of prostate cancer except transurethral resection\n             performed within 4 months minimum before radiotherapy,\n\n          9. Age \u2265 18 years and \u2264 85 years\n\n         10. ECOG performance status \u2264 1,\n\n         11. Estimated life expectancy > 5 years\n\n         12. Membership of a social security system,\n\n         13. Signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Prostate cancer histology other than adenocarcinoma,\n\n          2. pN1 patients (lymph node dissection after histologically proven)\n\n          3. PSA > 100 ng/ml\n\n          4. History of cancer within 5 years prior to trial entry (with the exception of basal\n             cell carcinoma skin)\n\n          5. Patient with severe hypertension uncontrolled by appropriate treatment (\u2265 160 mm Hg\n             systolic and / or \u2265 90 mm Hg diastolic)\n\n          6. Contra-indication for pelvic irradiation (eg scleroderma, chronic inflammatory\n             disease of the digestive tract, etc ...)\n\n          7. Contra-indication to agonists or antagonists of LH-RH\n\n          8. Bilateral hip prosthesis,\n\n          9. Patients already included in another clinical trial with an experimental molecule,\n\n         10. Persons deprived of liberty or under guardianship\n\n         11. Unable to undergo medical test for geographical, social or psychological."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704027", 
            "org_study_id": "2012-A00694-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Radiotherapy", 
                "description": "Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :\nPelvis : 55,5 Gy (1,85 Gy/fr)\nSeminal vesicles : 66 Gy (2,2 Gy/fr)\nProstate : 72 Gy (2,4 Gy/fr)", 
                "intervention_name": "Simultaneous integrated boost intensity-modulated arctherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Radiotherapy", 
                "description": "Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.", 
                "intervention_name": "Androgen deprivation", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Androgens"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Localized", 
            "High risk"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dijon", 
                    "country": "France", 
                    "state": "Burgundy", 
                    "zip": "21079"
                }, 
                "name": "Centre Georges-Fran\u00e7ois Leclerc"
            }, 
            "investigator": {
                "last_name": "Etienne Martin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective Phase II Study Evaluating the Feasibility of a Conformational Pelvic and Prostatic Radiotherapy With Simultaneous Integrated Boost Modulated-intensity Arctherapy (SIB-IMAT) in Combination With Long Term Androgen Deprivation for High Risk Localized Prostate Cancer.", 
        "overall_contact": {
            "email": "jskrzypski@cgfl.fr", 
            "last_name": "J\u00e9r\u00e9my SKRZYPSKI, PhD", 
            "phone": "3 80 73 77 51", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "stiago@cgfl.fr", 
            "last_name": "Sandrine TIAGO", 
            "phone": "3 45 34 80 51", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Centre Georges-Fran\u00e7ois Leclerc", 
            "last_name": "Etienne MARTIN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Acute urinary and rectal toxicities will be assessed according to the NCI CTCAE v4.0 quotation each week during radiotherapy treatment period up to six months after the end of the radiotherapy treatment period.", 
            "measure": "Number of Participants with Acute urinary and rectal toxicities as a Measure of treatment specific Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "From start of radiotherapy to six months after the end of radiotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the late urinary and rectal toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "for each patient every 6 months after the end of radiotherapy up to 5 years."
            }, 
            {
                "measure": "Evaluate the 5-year biochemical-free survival", 
                "safety_issue": "No", 
                "time_frame": "for each patient from zero day up to 7 day after the end of radiotherapy, 6 weeks, 3 months, and every 6 months after the end of radiotherapy up to 5 years."
            }, 
            {
                "measure": "Evaluate the metastase-free survival", 
                "safety_issue": "No", 
                "time_frame": "for each patient from zero day up to 7 day after the end of radiotherapy, 6 weeks, 3 months, and every 6 months after the end of radiotherapy up to 5 years."
            }, 
            {
                "measure": "To evaluate the specific survival", 
                "safety_issue": "No", 
                "time_frame": "for each patient from inclusion up to 5 years after the end of radiotherapy."
            }, 
            {
                "measure": "To evaluate the overall survival", 
                "safety_issue": "No", 
                "time_frame": "for each patient from inclusion up to 5 years after the end of radiotherapy."
            }, 
            {
                "measure": "To evaluate the quality of life", 
                "safety_issue": "No", 
                "time_frame": "inclusion day, from zero day up to 7 day after the end of radiotherapy, 6 weeks after the end of the radiotherapy, 3 months after the end of the radiotherapy, every 6 months after the end of radiotherapy up to 5 years."
            }
        ], 
        "source": "Centre Georges Francois Leclerc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Georges Francois Leclerc", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}